Document b5vyxq7Lo9xzmNbgQND8Zrx7o

So : 30 Chemicals. n U23M7Ce5nlte1r t. a ARZIG - 062] 3M November 2, 1998 Charles M. Auer, Director Chemical Control Division USS. Environmental Protection Agency 40M1 Street, S.W. Washington, D.C. 20460 RE: Mesting Request to Discuss Fluorochemicals Dear Mr. Auer: 2 ox S T o 3: 2 25 5 a `This lemer is to reconfirm 3M Company's request to mest with you and your sf to discuss fre acosospeesrsamteinotnibnietriwateisvnestfhoerApgeernfcluyoraonodctthneecsoumlfpoannayteo(rPFteOsSt)in-gb,apsreoddufcltuosrtoecwhaermdischailps.aAndsddisekscribed in 3M's samples TfrSoCmAinSdeicvtiidounal3s(w)itshubnmoisksnioownnofocMcaupyat1i5o,na1l99e8x,p3osMurheaslodwetPecFtOeSd in U.S. levels blood bark in tke bloc at PapFpOrSoxilemvaetleslayre30coptarktnsopwernabilltihiosn t(ipmpeb,) bountacvoeurladgeb.e rTehleateexdptoostuhreeppraotduhcwta,ysusreeasnpdo/nosriiceisfgoorsatlheosfe products manufactured by 3M and its customers. i[n2 h3uMm'anjusdegrmuemntp,recsuernrteantsiingfniofrimcaatnitohneaalntdhdraitskz.doFonrotovdeermotnhisrttryayteeartsh,athtukmeaPnFsOeSrulmevhelassmbeeaesnured Known to contain organic 0 comprise a measurable fluorine at fractionof pob levels. Recently, 3M has determined human organic fluorine levels. Based og that over PFOS'2gpears twenty ears o5fM'mesdfilcuaolramcohneirtmoircailngpraondducetpiiodnemwioorlkoegrisca(lsicnagtlae, dhiogwitevpearrt,stpheerPmFiOllSiobnl(opcpdml)evleelvselisd)eaxretesodtin saisusdoycioafte3dMw'isthAuaonryohcehmeamtioclaolgipcraold,uhctoiromnonwaolrkoerrcslidniidcanlotcheimnidisctartye cahnayngdeiss.easSeimcialtaergloy,ry2imnoerxacleistsy of expected. Nonetheless. the findingof low ppb PEOS levels in the blood of te general populatioz 20d tse use and distribution patterns of PFOS-based flucrochemicals has led 3M management 10 undertake a comprehensive testing and product siewardship program for these chemicals. Tais program includes the following components: + Animal testing of PFOS and other fluorachemicals which may breakdown or cmaertcaibnoolgiezneictiotyPFaOndS rienproordduecrttoiveeveaflfueacttse)aarnadngbeettoefrtdoexfiicnoeloKgiinceatlicasda-npodibnitoslo(giincacllufdaitneg ofthese chemicals in rodent and primate species.' : e1n3eMraatlisoonleredpraondduc8t(iev)ersetpuodritesonopSePpFtOemSbaenrd14e,th1y99f8osperoavlciodhionlg.prelimina'ry results fom two- Fey page2 Charles M. Auer, Director Environmental fate and effects studies to better characterize environmental exposure pathways for PFOS and its potential ecotoxicity. Evaluationoflife-cycle exposures for industrial and consumer fluorochemical products that could breakdown or metabolize to PFOS inorderto better characterize the nature, `magnitude and extentofpotential PFOS exposure by workers and the general population. + Product reformulation, including reductionofresiduals in 3M products, to minimize exposureofdownstream users to PFOS-based fluorochemicals. Additionally, customer communication initiatives, including revised MSDSs and a stewardship program are underway. To support this program, 3M has created an independent Scientific Advisory Panel comprised of recognized experts in relevant disciplines. 3M also is working with a range of outside consultants to assist us in the program described above. 3M wishes to meet with you in the immediate future to discuss the recent finding of PFO levels in human blood and to review its testing and product stewardship program. 3M's management is committed to working in partnership with EPA on risk assessment and risk management issues for PFOS-based fluorochemicals and would like to develop a framework for ongoing dialogue and collaboration with EPA as our efforts continue. We would like to schedule a meeting with you during the week of December 14%,ifyour schedule permits. 3M also has received the recent letter from Administrator Browne inviting participation in EPA's testing initiative for High Production Volume (HPV) chemicals. We would like to take the opportunity at the upcoming meeting, should EPA wish, to provide an update on 3M''s activities to develop a response to this letter. Representing 3M at the meeting will be myself, along with Dr. Charles Reich, Group Vice President, Chemical Markets Group; Dr. Larry R. Zobel, M.D. MPH,Staff Vice President and Medical Director, 3M Medical Department; and Dan Hakes, Product Steward Specialist. Please call me at 651/733-6374 to confirm a date and time for the meeting. Sincerely yours, Hriitioons OQ Fhegmmin, William A. Weppner, Ph.D. Director of Environmental, Health, . Safety & Regulatory Affairs for the 3M Chemical Markets Group cc: PFarualnkCaCmopvaenrella - David Williams 2